![]() development was later discontinued, and the discovery that inhibition of PNP activates the immune system, rather than suppressing it. The decision to develop LR 09 for the treatment of relapse after stem cell transplantation follows the achievement of complete remission in a three-year-old patient using a pharmacologically analogous PNP inhibitor, whose U.S. LR 09 is a novel form of the small molecule drug, Ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor that was originally developed for the treatment of autoimmune and inflammatory disorders. LR 09 is a novel metabolic immune checkpoint inhibitor, for the treatment of patients with hematological malignancies who are diagnosed with a relapse after allogeneic stem cell transplant (SCT). ![]() Food and Drug Administration (FDA) has granted orphan drug designation for LR 09. ![]() ![]() Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |